Brain Ischemia,Stoke Clinical Trial
Official title:
Dyslipidemia Management in Chinese Post Stroke Patients
| Verified date | July 2015 |
| Source | AstraZeneca |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | China: Food and Drug Administration |
| Study type | Observational |
The purpose of this study is to provide current and reliable data of dyslipidimia management
together with control situation of blood pressure and glucose for post-stroke patients
within 6-12 months from attack, and also the association between patient characteristics and
control rate of lipids in this population.
It is an non-interventional study, no study specified treatment is required.Approximately
5000 post ischemic stroke patients within 6-12 months from attack will enter into the study.
Fifty centres from different regions of China will participate in this study.
| Status | Completed |
| Enrollment | 5000 |
| Est. completion date | August 2014 |
| Est. primary completion date | August 2014 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. Male or female with age = 18 years 2. Post ischemic stroke patients within 6-12 months from attack 3. written informed consent is provided to participant in the study Exclusion Criteria: 1. Significant medical or psychological condition that make patients can not finish the questionnaire independently or with the aids of his/her legal representatives 2. The patient is or will be in another clinical study 3. Previous enrolment in the present study |
Observational Model: Case-Crossover, Time Perspective: Cross-Sectional
| Country | Name | City | State |
|---|---|---|---|
| China | Research Site | Beijing | Beijing |
| China | Research Site | Beijing | |
| China | Research Site | Changchun | Jilin |
| China | Research Site | Changsha | Hunan |
| China | Research Site | Chengdu | Sichuan |
| China | Research Site | Chongqing | Sichuan |
| China | Research Site | Guangzhou | |
| China | Research Site | Guangzhou | Guangdong |
| China | Research Site | Haerbin | Heilongjiang |
| China | Research Site | Hangzhou | Zhejiang |
| China | Research Site | Jinan | Shandong |
| China | Research Site | Nanjing | Jiangsu |
| China | Research Site | Qingdao | Shandong |
| China | Research Site | Ruian | Zhejiang |
| China | Research Site | Shanghai | Shanghai |
| China | Research Site | Shanghai | |
| China | Research Site | Shenyang | Liaoning |
| China | Research Site | Shenzhen | Guangdong |
| China | Research Site | Suzhou | Jiangsu |
| China | Research Site | Taizhou | Zhejiang |
| China | Research Site | Tianjin | Tianjin |
| China | Research Site | Wenzhou | Zhejiang |
| China | Research Site | Wuhan | Hubei |
| China | Research Site | Xi An | Shanxi |
| China | Research Site | Zhengzhou | Henan |
| China | Research Site | Zhenzhou | Henan |
| Lead Sponsor | Collaborator |
|---|---|
| AstraZeneca |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To observe LDL-C level of China post-stroke patients within 6-12 months from attack | Investigator will collect lab test results including blood lipid (i.e. Triglyceride, Total Cholesterol, LDL-C, HDL-C) during the patient visit. | Up to 12 months | No |
| Primary | To observe control rate of LDL-C of China post-stroke patients within 6-12 months from attack | Up to 12 months | No |